Multi-Epitope Vaccine Design against Monkeypox Virus via Reverse Vaccinology Method Exploiting Immunoinformatic and Bioinformatic Approaches

• Published in: Vaccines (Basel) Vol. 10; no. 12; p. 2010
• Main Authors: Bhattacharya, Kunal, Shamkh, Israa M, Khan, Mohammad Shahbaz, Lotfy, Marwa M, Nzeyimana, Jean Bosco, Abutayeh, Reem Fawaz, Hamdy, Nadia M, Hamza, Dalia, Chanu, Nongmaithem Randhoni, Khanal, Pukar, Bhattacharjee, Atanu, Basalious, Emad B
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.11.2022; MDPI
• Subjects: Allergenicity; Antigenic determinants; Antigenicity; Antigens; Bacterial infections; Biocompatibility; Bioinformatics; Cloning; Cloning vectors; Computational biology; Control; Design; Design and construction; DNA viruses; E coli; Epitopes; Genomes; Health aspects; Immune response; Immune system; immunoinformatics; In vivo methods and tests; Lymphocytes B; Lymphocytes T; Mass production; Methods; Monkeypox; monkeypox virus; multi-epitope vaccine; Pharmaceutical industry; Proteins; Proteomics; reverse vaccinology; Smallpox vaccine; Toxicity; Vaccines; Viruses; India; reverse vaccinology; immunoinformatics; monkeypox virus; bioinformatics; multi-epitope vaccine
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10122010

(1) Background: The monkeypox virus is a zoonotic orthopox DNA virus that is closely linked to the virus. In light of the growing concern about this virus, the current research set out to use bioinformatics and immunoinformatics to develop a potential vaccine against the virus. (2) Methods: A multiepitope vaccine was constructed from the B-cell and T-cell epitopes of the MPXVgp181 strain using adjuvant and different linkers. The constructed vaccine was predicted for antigenicity, allergenicity, toxicity, and population coverage. In silico immune simulation studies were also carried out. Expression analysis and cloning of the constructed vaccine was carried out in the pET-28a(+) vector using snapgene. (3) Results: The constructed vaccine was predicted to be antigenic, non-allergenic, and non-toxic. It was predicted to have excellent global population coverage and produced satisfactory immune response. The in silico expression and cloning studies were successful in , which makes the vaccine construct suitable for mass production in the pharmaceutical industry. (4) Conclusion: The constructed vaccine is based on the B-cell and T-cell epitopes obtained from the MPXVgp181 strain. This research can be useful in developing a vaccine to combat the monkeypox virus globally after performing in-depth in vitro and in vivo studies.